- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Mindray Launches New TE Air Handheld Ultrasound Device
The TE Air is reportedly the first handheld ultrasound device to offer dual connectivity to mobile devices or touch-based ultrasound systems.
Offering the promise of enhanced connectivity and dedicated presets for a variety of clinical exams, Mindray has launched TE Air, a wireless handheld ultrasound modality.
Mindray said the TE Air offers enhanced utility and accessibility, claiming that the device is the first handheld ultrasound that can be connected to mobile devices or the touch-based TE X Ultrasound System.
“The TE Air is a leap forward in ultrasound technology, offering comprehensive functionality inside or outside the hospital environment,” noted Wayne Quinn, the president of Mindray North America. “The new 2-in-1 innovative solution empowers clinicians to overcome the traditional constraints of cords and confined spaces, giving them access to premium scanning capability when and where they need it.”
The company noted a number of additional features with TE Air including:
• a phased array with exam presets for a variety of clinical exams including cardiac exams, transcranial imaging, lung imaging and OB/GYN exams;
• single crystal technology that facilitates high-resolution imaging quality; and
• a waterproof design that allows for easy cleaning of the device with compatible disinfectant products.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
